Endo International PLC shares plunged in the extended session Thursday after the drug maker cut its outlook for the year. Endo shares dropped 25% to $19.92 after hours. The company said it now expects adjusted earnings of $4.50 to $4.80 on revenue of $3.87 billion to $4.03 billion for the year. Analysts surveyed by FactSet had forecast earnings of $5.68 a share on revenue of $4.3 billion. For the first quarter, Endo reported adjusted earnings of $1.08 a share on revenue of $964 million. Analysts had expected $1.05 a share on revenue of $960.3 million. Separately, Endo announced its head of U.S. branded pharmaceuticals, Brian Lortie, was stepping down once a successor is found.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News